DK2155180T3 - Lægemiddelkombination og dets anvendelse til behandling af muskeltab - Google Patents

Lægemiddelkombination og dets anvendelse til behandling af muskeltab Download PDF

Info

Publication number
DK2155180T3
DK2155180T3 DK08737103.5T DK08737103T DK2155180T3 DK 2155180 T3 DK2155180 T3 DK 2155180T3 DK 08737103 T DK08737103 T DK 08737103T DK 2155180 T3 DK2155180 T3 DK 2155180T3
Authority
DK
Denmark
Prior art keywords
formoterol
product
treatment
megestrol
muscle
Prior art date
Application number
DK08737103.5T
Other languages
English (en)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707930A external-priority patent/GB0707930D0/en
Priority claimed from GB0707931A external-priority patent/GB0707931D0/en
Priority claimed from GB0710101A external-priority patent/GB0710101D0/en
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Application granted granted Critical
Publication of DK2155180T3 publication Critical patent/DK2155180T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Claims (9)

1. Produkt omfattende formoterol og megestrol, og som ikke omfatter et makrolid, som et kombineret præparat til separat, samtidig eller sekventiel anvendelse ved behandling eller forebyggelse af muskeltab i forbindelse med cancer kakeksi.
2. Produkt til anvendelse ifølge krav 1, hvor megestrolet er acetatsaltet.
3. Produkt ifølge krav 1 omfattende R,R-formoterol og megestrol, som et kombineret præparat til separat, samtidig eller sekventiel anvendelse ved behandling eller forebyggelse af muskeltab i forbindelse med cancer kakeksi.
4. Produkt til anvendelse ifølge et hvilket som helst af de foregående krav, til oral administration.
5. Produkt til anvendelse ifølge et hvilket som helst af de foregående krav, endvidere omfattende et korti kosteroid.
6. Formoterol til anvendelse til behandling eller forebyggelse af muskeltab i forbindelse med cancer kakeksi, hvor individet der behandles også behandles med megestrol men ikke med et makrolid.
7. Megestrol til anvendelse til behandling eller forebyggelse af muskeltab i forbindelse med cancer kakeksi, hvor individet der behandles også behandles med formoterol men ikke med et makrolid.
8. Megestrol til anvendelse ifølge krav 7, hvor megestrolet er acetatsaltet.
9. Formoterol til anvendelse ifølge krav 6 hvor megestrolet er acetatsaltet.
DK08737103.5T 2007-04-24 2008-04-24 Lægemiddelkombination og dets anvendelse til behandling af muskeltab DK2155180T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0707930A GB0707930D0 (en) 2007-04-24 2007-04-24 New therapeutic use
GB0707931A GB0707931D0 (en) 2007-04-24 2007-04-24 New Therapeutic use
GB0710101A GB0710101D0 (en) 2007-05-25 2007-05-25 New Therapeutic use
PCT/GB2008/001452 WO2008129308A2 (en) 2007-04-24 2008-04-24 Drug combination and its use in the treatment of muscle loss

Publications (1)

Publication Number Publication Date
DK2155180T3 true DK2155180T3 (da) 2016-09-12

Family

ID=39639100

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08737103.5T DK2155180T3 (da) 2007-04-24 2008-04-24 Lægemiddelkombination og dets anvendelse til behandling af muskeltab

Country Status (16)

Country Link
US (1) US8653052B2 (da)
EP (1) EP2155180B1 (da)
JP (1) JP5627452B2 (da)
KR (1) KR101546977B1 (da)
CN (2) CN104306381A (da)
AU (1) AU2008240379B2 (da)
BR (1) BRPI0810461A2 (da)
CA (1) CA2721739C (da)
DK (1) DK2155180T3 (da)
EA (1) EA018918B1 (da)
ES (1) ES2592289T3 (da)
HK (1) HK1202262A1 (da)
IL (1) IL201426A (da)
MX (1) MX2009011294A (da)
NZ (1) NZ580975A (da)
WO (1) WO2008129308A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121111B1 (en) 1998-10-15 2010-02-10 Imperial Innovations Limited Compounds for the treatment of weight loss
ATE552032T1 (de) 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
CN103269693A (zh) * 2010-11-24 2013-08-28 利赛拉公司 选择性、亲脂性及长效型β激动剂单一治疗调配物和用于肥胖及外形凸起的美容治疗的方法
WO2016021191A1 (en) * 2014-08-05 2016-02-11 Raqualia Pharma Inc. Serine derivatives as ghrelin receptor agonists
KR102530724B1 (ko) * 2020-01-13 2023-05-09 아스트로메디컬 바이오테크놀로지, 리미티드 악액질의 치료에서의 케타민의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308157B1 (en) 1987-09-15 1997-02-26 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
EP2263650A3 (en) * 2002-04-12 2013-12-25 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
ES2245612B1 (es) * 2004-06-29 2007-08-16 Universidad De Barcelona Nuevo uso terapeutico del formoterol.
JP2009526087A (ja) * 2005-12-22 2009-07-16 アナボレックス， インコーポレイテッド 悪液質の予防および処置のための組成物および方法
US7947579B2 (en) * 2006-02-13 2011-05-24 Stc.Unm Method of making dense, conformal, ultra-thin cap layers for nanoporous low-k ILD by plasma assisted atomic layer deposition

Also Published As

Publication number Publication date
KR20100017205A (ko) 2010-02-16
US20100130456A1 (en) 2010-05-27
IL201426A (en) 2016-09-29
AU2008240379A1 (en) 2008-10-30
WO2008129308A2 (en) 2008-10-30
NZ580975A (en) 2012-10-26
WO2008129308A3 (en) 2009-12-17
KR101546977B1 (ko) 2015-08-24
CA2721739A1 (en) 2008-10-30
AU2008240379B2 (en) 2012-10-04
CN104306381A (zh) 2015-01-28
IL201426A0 (en) 2010-05-31
EA200970957A1 (ru) 2010-04-30
CN101730547A (zh) 2010-06-09
CA2721739C (en) 2016-08-23
EP2155180A2 (en) 2010-02-24
JP5627452B2 (ja) 2014-11-19
HK1202262A1 (en) 2015-09-25
EP2155180B1 (en) 2016-07-13
MX2009011294A (es) 2010-01-29
US8653052B2 (en) 2014-02-18
BRPI0810461A2 (pt) 2014-10-14
EA018918B1 (ru) 2013-11-29
JP2010525044A (ja) 2010-07-22
ES2592289T3 (es) 2016-11-29

Similar Documents

Publication Publication Date Title
DK2155180T3 (da) Lægemiddelkombination og dets anvendelse til behandling af muskeltab
TWI629058B (zh) 醫藥組成物及其用途
RU2617502C2 (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
TWI492745B (zh) 合成的三萜系化合物及其使用於治療疾病之方法
KR101996245B1 (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
JP2023030091A (ja) ポネシモドを含有する医薬的組み合わせ
US20200397721A1 (en) Methods of Treating or Preventing an Attention Disorder, Cognitive Disorder, and/or Dementia Associated with a Neurodegenerative Disorder
CA2671622C (en) Treatment of cachexia
HK1144555A (en) Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss
Lambert Cachexia-Prolonging Life
RU2569732C9 (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
HK1073795A (en) Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence